QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
QQQ   437.99 (-1.66%)
AAPL   174.93 (-0.06%)
MSFT   420.95 (-1.63%)
META   512.37 (-2.06%)
GOOGL   157.53 (-1.18%)
AMZN   185.59 (-1.83%)
TSLA   171.09 (-2.01%)
NVDA   886.80 (-2.14%)
AMD   162.90 (-4.46%)
NIO   4.11 (-7.85%)
BABA   71.95 (-3.87%)
T   16.33 (-0.55%)
F   12.60 (-3.37%)
MU   122.59 (-3.86%)
GE   154.08 (-2.11%)
CGC   7.96 (-2.33%)
DIS   114.27 (-2.46%)
AMC   2.67 (-4.64%)
PFE   25.88 (-1.75%)
PYPL   64.65 (-1.75%)
XOM   121.40 (-0.32%)
LON:INDV

Indivior (INDV) Share Price, News & Analysis

GBX 1,565
-67.00 (-4.11%)
(As of 04:35 PM ET)
Today's Range
1,537
1,664
50-Day Range
1,314
1,764
52-Week Range
1,125
1,938
Volume
292,626 shs
Average Volume
379,375 shs
Market Capitalization
£2.13 billion
P/E Ratio
156,500.00
Dividend Yield
0.96%
Price Target
GBX 2,515

Indivior MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
61.0% Upside
GBX 2,515 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
£42.45 M Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.76 out of 5 stars

INDV stock logo

About Indivior Stock (LON:INDV)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

INDV Stock Price History

INDV Stock News Headlines

Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Adial Announces Appointment of Tony Goodman as Chief Operating Officer
Indivior PLC (INDV): Unveiling Its Market Value
Indivior to Commence Trading on Nasdaq
INDV.L - Indivior PLC
See More Headlines
Receive INDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
1,164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
GBX 2,515
High Stock Price Target
GBX 2,700
Low Stock Price Target
GBX 2,330
Potential Upside/Downside
+61.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
£2 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£1.09 billion
Cash Flow
GBX 582.81 per share

Miscellaneous

Free Float
N/A
Market Cap
£2.12 billion
Optionable
Not Optionable
Beta
-0.05
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Mark Crossley
    CEO & Executive Director
  • Mr. Ryan Preblick
    CFO & Executive Director
  • Dr. Christian Heidbreder
    Chief Scientific Officer
  • Mr. Jason Thompson
    Vice President of Investor Relations
  • Ms. Cynthia Cetani
    Chief Integrity & Compliance Officer
  • Mr. Jeffrey W. Burris (Age 52)
    Chief Legal Officer
  • Mr. Jon Fogle
    Chief Human Resources Officer
  • Mr. Richard Simkin
    Chief Commercial Officer
  • Mr. Hillel West
    Chief Manufacturing & Supply Officer
  • Mr. Vishal Kalia
    SVP of US Treatment Access, Support Programs & Business Insights and Chief Impact & Strategy Officer

INDV Stock Analysis - Frequently Asked Questions

Should I buy or sell Indivior stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INDV shares.
View INDV analyst ratings
or view top-rated stocks.

What is Indivior's stock price target for 2024?

1 equities research analysts have issued 12 month price objectives for Indivior's shares. Their INDV share price targets range from GBX 2,330 to GBX 2,700. On average, they anticipate the company's stock price to reach GBX 2,515 in the next twelve months. This suggests a possible upside of 61.0% from the stock's current price.
View analysts price targets for INDV
or view top-rated stocks among Wall Street analysts.

How have INDV shares performed in 2024?

Indivior's stock was trading at GBX 1,185 at the beginning of the year. Since then, INDV shares have increased by 31.8% and is now trading at GBX 1,562.
View the best growth stocks for 2024 here
.

Is Indivior a good dividend stock?

Indivior (LON:INDV) pays an annual dividend of GBX 15 per share and currently has a dividend yield of 4.48%. INDV has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 150,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

What other stocks do shareholders of Indivior own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF).

How do I buy shares of Indivior?

Shares of INDV stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

This page (LON:INDV) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners